Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael T Tetzlaff

Showing results (151-160 of 224) with videos related to

Pageof 23
Sort By:
Journal of Cutaneous Pathology|April 19, 2016
Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptionsGeorge Jour, Isabella C Glitza, Rachel M Ellis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2018
Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic AlterationsMichael T Tetzlaff, Jonathan L Curry, Jing Ning, et al.
The American Journal of Dermatopathology|June 5, 2018
Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic PitfallJonathan L Curry, Michael T Tetzlaff, Sa A Wang, et al.
Cancer Discovery|April 17, 2019
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid TumorsSalah-Eddine Bentebibel, Michael E Hurwitz, Chantale Bernatchez, et al.
The Journal of Pathology|June 12, 2016
Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinomaMichael T Tetzlaff, Rajesh R Singh, Elena G Seviour, et al.
Cancers|January 1, 2020
Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral MelanomaDinesh Pradhan, George Jour, Denái Milton, et al.
Journal of Cutaneous Pathology|September 14, 2017
Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patientsMichael T Tetzlaff, Amir A Jazaeri, Carlos A Torres-Cabala, et al.
Journal of Cutaneous Pathology|March 19, 2019
Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14<sup>+</sup> and CD16<sup>+</sup> monocytes driving an innate immune responseJonathan L Curry, Alexandre Reuben, Robert Szczepaniak-Sloane, et al.
Technology in Cancer Research & Treatment|January 19, 2006
Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancerMichael T Tetzlaff, Bin S Teh, Terry L Timme, et al.
Pigment Cell & Melanoma Research|April 24, 2015
miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatmentShujing Liu, Michael T Tetzlaff, Tao Wang, et al.
Pageof 23

Showing results (151-160 of 224) with videos related to

Sort By:
Pageof 23
Journal of Cutaneous Pathology|April 19, 2016
Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptionsGeorge Jour, Isabella C Glitza, Rachel M Ellis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2018
Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic AlterationsMichael T Tetzlaff, Jonathan L Curry, Jing Ning, et al.
The American Journal of Dermatopathology|June 5, 2018
Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic PitfallJonathan L Curry, Michael T Tetzlaff, Sa A Wang, et al.
Cancer Discovery|April 17, 2019
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid TumorsSalah-Eddine Bentebibel, Michael E Hurwitz, Chantale Bernatchez, et al.
The Journal of Pathology|June 12, 2016
Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinomaMichael T Tetzlaff, Rajesh R Singh, Elena G Seviour, et al.
Cancers|January 1, 2020
Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral MelanomaDinesh Pradhan, George Jour, Denái Milton, et al.
Journal of Cutaneous Pathology|September 14, 2017
Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patientsMichael T Tetzlaff, Amir A Jazaeri, Carlos A Torres-Cabala, et al.
Journal of Cutaneous Pathology|March 19, 2019
Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14<sup>+</sup> and CD16<sup>+</sup> monocytes driving an innate immune responseJonathan L Curry, Alexandre Reuben, Robert Szczepaniak-Sloane, et al.
Technology in Cancer Research & Treatment|January 19, 2006
Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancerMichael T Tetzlaff, Bin S Teh, Terry L Timme, et al.
Pigment Cell & Melanoma Research|April 24, 2015
miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatmentShujing Liu, Michael T Tetzlaff, Tao Wang, et al.
Pageof 23